Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 14/20 | 0.72 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12119609 | 0.99 | PTGFR (0.73) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL12119720 | 0.98 | PTGFR (0.73) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL21546227 | 0.96 | PTGFR (0.74) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL12119717 | 0.96 | PTGFR (0.74) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL13949002 | 0.95 | PTGFR (0.69) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL12119570 | 0.94 | PTGFR (0.71) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL21939579 | 0.94 | PTGFR (0.71) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL12119619 | 0.94 | PTGFR (0.67) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL13949004 | 0.94 | PTGFR (0.67) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL13327958 | 0.93 | PTGFR (0.68) | PTGFRPTGER3ABCC4ABCB11TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643702-A1 | PROSTAGLANDIN DERIVATIVES | Nicox S.A. (FR) | 2020-04-29 | — | — | EP | disclosed |
| EP-3002277-B1 | PROSTAGLANDIN DERIVATIVES | NICOX SA (FR) | 2019-11-06 | — | — | EP | disclosed |
| US-8058467-B2 | Prostaglandin derivatives | NICOX S.A. (FR) | 2011-11-15 | — | — | US | disclosed |
| US-20110136904-A1 | PROSTAGLANDIN DERIVATIVES | NICOX S.A. (FR) | 2011-06-09 | — | — | US | disclosed |
| US-7910767-B2 | Prostaglandin derivatives | NICOX S.A. (FR) | 2011-03-22 | — | — | US | disclosed |
| US-20100130507-A1 | PROSTAGLANDIN DERIVATIVES | NICOX S.A. (FR) | 2010-05-27 | — | — | US | disclosed |
| US-7629345-B2 | Prostaglandin derivatives | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20090030076-A1 | PROSTAGLANDIN DERIVATIVES | NICOX S.A. | 2009-01-29 | — | — | US | disclosed |
| US-7449469-B2 | Prostaglandin derivatives | NICOX S.A. (FR) | 2008-11-11 | — | — | US | disclosed |
| US-7273946-B2 | Nitroxy derivatives, e.g., 4-(nitrooxy)butyl [1R-[1 alpha (Z),2 alpha (R*),3 alpha ,5 alpha ]]-7-[3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl]-5-heptenoate; used for the treatment of glaucoma and ocular hypertension | NICOX S.A. (FR) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136904-A1 | PROSTAGLANDIN DERIVATIVES | PTGIS, PTGIR, PTGS1 | PTGFR 16/4885PTGER3 14/4885ABCC4 2025/4885 |
| US-20100130507-A1 | PROSTAGLANDIN DERIVATIVES | PTGIS, PTGIR, PTGS1 | PTGFR 16/4885PTGER3 14/4885ABCC4 2025/4885 |
| US-20090030076-A1 | PROSTAGLANDIN DERIVATIVES | PTGIS, PTGIR, PTGS1 | PTGFR 16/4885PTGER3 14/4885ABCC4 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.